Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

Back in No­vem­ber, the De­part­ment of Health and Hu­man Ser­vices took the rare step of fil­ing a com­plaint against Gilead for in­fring­ing on gov­ern­ment-owned patents re­lat­ed to the HIV drug Tru­va­da (emtric­itabine/teno­fovir diso­prox­il fu­marate) for pre-ex­po­sure pro­phy­lax­is (PrEP).

But on Thurs­day, Gilead filed its own re­tort, mak­ing clear that it does not be­lieve it has in­fringed on the Cen­ters for Dis­ease Con­trol and Pre­ven­tion’s (CDC) Tru­va­da patents be­cause they are in­valid.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.